ProCE Banner Activity

Slides on Targeting IL-13 in Moderate to Severe Atopic Dermatitis: Forging a New Path to Improved Disease and Patient Outcomes


Atopic dermatitis (AD) significantly impacts physical, social, and psychological well-being. Recently, novel, more effective treatment options have been approved, including those targeting interleukin-13. Download these slides for expert insights on incorporating these agents to optimize care for patients with moderate to severe AD.

Released: May 10, 2023



Terry Faleye

Terry Faleye, MPAS, PA-C

Dermatology Physician Assistant
DermSurgery Associates
Houston, Texas

Jonathan Silverberg

Jonathan Silverberg, MD, PhD, MPH

Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Provided by

Provided by Partners for Advancing Clinical Education (PACE)

ProCE Banner


This activity is supported by an educational grant from Lilly.



This program has been made available online.